What is claimed is:

1. Use of a botulinum toxin in the manufacture of a medicament for treating or preventing incontinence occurring during orgasm following a surgical procedure~~associated with sexual activity~~, wherein the medicament is to be administered to the bladder of a patient.

2. The use of claim 1, wherein the botulinum toxin is selected from the group consisting of types A, B, C, D, E, and, G.

3. The use of claim 2, wherein the botulinum toxin is at least one of type A or type B.

4. The use of claim 1, wherein the ~~incontinence associated with sexual activity occurs following a~~ surgical procedure is for a prostate disorder.

5. The use of claim 4, wherein the surgical procedure is selected from the group consisting of radical prostatectomy, laparoscopic radical prostatectomy, transurethral resection of the prostate, transurethral microwave therapy, transurethral needle ablation, and cryosurgery.

~~6. Use of a botulinum toxin in the manufacture of a medicament for preventing post-surgical incontinence associated with sexual activity, wherein the medicament is to be administered to the bladder of a patient, wherein the botulinum toxin is to be administered prior to the onset of incontinence.~~

~~7~~6. The use of ~~claim 6~~any of the preceding claims, wherein the medicament is for preventing incontinence occurring during ogasm following a surgical procedure, and the medicament is to be administered prior to the onset of incontinence~~ patient is to be administered the botulinum toxin at a time selected from the group consisting of before surgery, during surgery, after surgery, and combinations thereof~~.

~~8~~7. The use of claim ~~6~~7, wherein the patient is to be administered the ~~botulinum toxin~~medicament before surgery.

~~9~~8. The use of claim ~~7~~6, wherein the patient is to be administered the ~~botulinum toxin~~medicament during surgery.

~~10~~9. The use of claim ~~8~~7, wherein the patient is to be further administered ~~botulinum toxin~~the medicament after surgery.

~~11. Use of a botulinum toxin in the manufacture of a medicament for treating incontinence associated with sexual activity in a patient previously diagnosed with a urogenic abnormality.~~

~~12. The use of claim 11, wherein the botulinum toxin is selected from the group consisting of types A, B, C, D, E, and, G.~~

13. A method of treating incontinence ~~associated with sexual activity~~ occurring during orgasm comprising

a) administering a therapeutically effective amount of a botulinum toxin to the bladder of a patient in need thereof, and;

b) administering a therapeutically effective amount of an anticholinergic drug to a patient in need thereof;

thereby treating the incontinence associated with sexual activity.

14. The method of claim 10, wherein the botulinum toxin is selected from the group consisting of types A, B, C, D, E, and, G.

15. The method of claim 14, wherein the botulinum toxin is at least one of type A or type B.

16. Use of a botulinum toxin and an anticholinergic drug in the manufacture of a medicament for treating incontinence ~~associated with sexual activity~~occurring during orgasm, wherein the botulinum toxin is to be administered to the bladder of a patient, and wherein the anticholinergic drug is to be administered to the patient.

17. The use of claim 16, wherein the botulinum toxin is selected from the group consisting of types A, B, C, D, E, and, G.

18. The use of claim 17, wherein the botulinum toxin is at least one of type A or type B.